Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from May 1, 2014, to October 31, 2014, with the report dated November 12, 2014. The document serves as a Block Listing Six Monthly Return, detailing the status of various share option and savings-related share schemes. It does not contain general business operations updates or financial performance data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting the number of securities allotted and the remaining balance of unallotted securities under specific employee share schemes.
Material Changes in Share Schemes
The filing reports changes in the number of unallotted securities across ten distinct schemes. Key movements include:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: 975,646 securities were issued/allotted, reducing the unallotted balance from 7,354,187 to 6,378,541.
- GlaxoSmithKline Share Option Plan - ADS: 1,250,646 securities were issued/allotted, reducing the unallotted balance from 1,672,236 to 421,590.
- GlaxoSmithKline plc Sharesave plan 2012: The scheme was increased by 250,000 securities. Additionally, 90,584 securities were issued/allotted, resulting in a final unallotted balance of 189,289 (up from 29,873).
- Other Schemes: No securities were issued or allotted during the period for the Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, SmithKline Beecham 1989 (Approved/Unapproved), and GlaxoSmithKline Savings Related Share Option Scheme. Their balances remained unchanged from the previous return.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance report regarding share scheme administration.
Important Facts for Investors to Verify
- Total securities issued under the primary Ordinary Share and ADS option plans during the six-month period.
- The specific increase of 250,000 shares in the Sharesave plan 2012 and its impact on future dilution.
- The remaining pool of unallotted shares available for future grants across all listed schemes.
- Confirmation that no new share issuances occurred in the legacy SmithKline Beecham and Glaxo Wellcome schemes.